shortagewatch

Home / Companies / Laboratoire Riva

Company family

Laboratoire Riva: medicine shortages

As of 2 Nov 2026, 40 Laboratoire Riva products have a reported shortage across 1 countries, covering 23 medicines.

Products short40rank #50 of 464
Medicines23active ingredients
Countries1/16
New in 90 days00 vs market pace
Typical duration12.6 yearsmedian so far
Manufacturing85%demand-driven 3%

Where

Canada40

Which therapeutic classes

Nervous system11Cardiovascular system11Dermatologicals8Respiratory system6Digestive tract and metabolism3Cancer and immune system1

Why, compared with all companies

Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
Laboratoire RivaLaboratoire Riva: Manufacturing problem 33 (82%)82%Laboratoire Riva: Increased demand 1 (2%)Laboratoire Riva: Distribution or logistics 3 (8%)8%Laboratoire Riva: Other 2 (5%)5%Laboratoire Riva: Not stated 1 (2%)All companiesAll companies: Manufacturing problem 4,893 (36%)36%All companies: Increased demand 1,873 (14%)14%All companies: Active ingredient shortage 367 (3%)All companies: Distribution or logistics 336 (2%)All companies: Commercial decision or withdrawal 435 (3%)All companies: Regulatory or licensing 131 (1%)All companies: Other 1,244 (9%)9%All companies: Not stated 4,221 (31%)31%

Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.

When its current shortages began

00112Dec: 0Jan ’25: 0Feb: 0FebMar: 0Apr: 1May: 0MayJun: 2Jul: 0Aug: 0AugSep: 0Oct: 0Nov: 0NovDec: 0Jan ’26: 0Feb: 0FebMar: 0Apr: 0May: 0MayJun: 0Jul: 0Aug: 0AugSep: 0Oct: 0Nov: 0Nov

Long-run trend in Canada

Canada dashboard
061218252017: 2520172018: 1520182019: 920192020: 220202021: 120212022: 420222023: 220232024: 920242025: 52025

Canada publishes every report since 2017, so it shows whether this company is reporting more or fewer shortages over time. The current year is partial.

Against its peers

Viatris995Teva903Sandoz599Pfizer491Accord (Intas)484Stada349Zentiva340Fresenius Kabi339Apotex326Sun Pharma250Aurobindo226Towa (Pensa)201Krka187Sanofi158Laboratoire Riva40

Breadth vs depth

1101001,00010,0001101001,000Products short (log scale)Medicines affected (log scale)Viatris: 995 / 248ViatrisTeva: 903 / 289TevaSandoz: 599 / 198SandozPfizer: 491 / 122PfizerAccord (Intas): 484 / 151Accord (Intas)Stada: 349 / 140Zentiva: 340 / 159ZentivaFresenius Kabi: 339 / 81Apotex: 326 / 152Sun Pharma: 250 / 77Aurobindo: 226 / 111Towa (Pensa): 201 / 102Krka: 187 / 67Sanofi: 158 / 45Jamp: 151 / 74Baxter: 149 / 27Sawai: 148 / 68Hikma: 126 / 44Glenmark: 105 / 39Sanis: 98 / 54Cheplapharm: 86 / 28GSK: 85 / 38Advanz (Amdipharm): 81 / 24Nichi-Iko: 77 / 29Takeda: 76 / 10Johnson & Johnson: 75 / 19Neuraxpharm: 75 / 19Novartis: 70 / 32Bayer: 68 / 17Biomed: 64 / 21Daiichi Sankyo: 59 / 18Orifarm: 59 / 40Medochemie: 56 / 14Pharmascience: 51 / 32Marcan: 51 / 16Doc Generici: 50 / 25B. Braun: 49 / 17AA Pharma: 46 / 26H E: 46 / 15Octapharma: 42 / 6Jv E: 42 / 1Kyowa Pharmaceutical: 42 / 16Novo Nordisk: 41 / 8Odan: 41 / 31Aspen: 41 / 13Sterop: 41 / 16Nipro: 41 / 17Dr. Reddy's: 40 / 24Organon: 40 / 20Kern Pharma: 40 / 30Bausch Health: 39 / 30Bracco: 38 / 6G.L.: 38 / 13Tatsumi Kagaku: 38 / 24Otsuka: 37 / 4Eli Lilly: 37 / 12Piramal Critical: 35 / 13Imuna Pharm: 35 / 4AbbVie: 34 / 15Medical Valley: 34 / 8Orion: 34 / 24Rowex: 34 / 19Takata Pharmaceutical: 33 / 17Aristo: 32 / 16Norgine: 32 / 3Gedeon Richter: 31 / 11Eql: 31 / 9Guerbet: 30 / 5Lukas Heil-Betriebsst: 30 / 0Roche: 29 / 14Omega: 29 / 18Bgp: 29 / 18Holsten -: 29 / 3Menarini: 29 / 17Paladin: 28 / 17Grifols: 28 / 9Ge: 28 / 6Merck & Co. (MSD): 27 / 14Ferring: 27 / 7Laboratoire Riva: 40 / 23Laboratoire Riva

Further right: more products short. Higher: more different medicines affected.

Medicines short

MedicineWhere this company is shortProductsEarliest startMain reasonShort anywhere
Betamethasone711 Apr 2014Manufacturing problem4/16
Simvastatin531 Oct 2018Manufacturing problem9/16
Pravastatin311 Apr 2014Manufacturing problem6/16
Atomoxetine22 Jun 2025Distribution or logistics11/16
Gabapentin211 Apr 2014Manufacturing problem9/16
Hydrocortisone211 Apr 2014Manufacturing problem1/16
Paracetamol220 Jun 2020Manufacturing problem10/16
Ranitidine213 Sep 2019Other1/16
Anastrozole121 May 2024Manufacturing problem5/16
Beclometasone111 Apr 2014Manufacturing problem2/16
Codeine1not givenNot stated2/16
Codeine and Paracetamol131 Oct 2018Manufacturing problem4/16
Combinations111 Apr 2014Manufacturing problem1/16
Diphenhydramine111 Apr 2014Manufacturing problem2/16
Donepezil112 Jan 2024Manufacturing problem8/16
Lansoprazole130 Apr 2025Distribution or logistics8/16
Levetiracetam15 Oct 2018Manufacturing problem9/16
Minoxidil111 Apr 2014Manufacturing problem4/16
Opium Derivatives and Expectorants111 Apr 2014Manufacturing problem2/16
Rizatriptan128 Apr 2017Manufacturing problem6/16
Theophylline111 Apr 2014Manufacturing problem3/16
Verapamil120 Oct 2016Manufacturing problem5/16
Zolmitriptan114 Oct 2016Manufacturing problem4/16

Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.